Recruiting NCT06821945
This summary needs review. Please check the official study record and contact the research team for details.
In Daegu Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug i A study involving a medication or substance. Over 19 Years
Countries South Korea
Sponsor Boryung Pharmaceutical Co., Ltd
Condition Schizophrenia Recruiting NCT07225712
This summary needs review. Please check the official study record and contact the research team for details.
In Fukuoka Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug Over 18 Years
Countries Japan
Sponsor Otsuka Pharmaceutical Co., Ltd.
Condition Schizophrenia Recruiting NCT07459647
The registry lists this study as recruiting. Study locations are listed in the United States.
Multiple locations, including Little Rock Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 65 Years
Countries United States
Sponsor MapLight Therapeutics
Condition Schizophrenia Recruiting NCT07423546
This summary needs review. Please check the official study record and contact the research team for details.
In New York Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 50 Years
Countries United States
Sponsor New York State Psychiatric Institute
Condition Schizophrenia Recruiting NCT07410507
The registry lists this study as recruiting. Study locations are listed in the United States, in Argentina, in Brazil, ...
Multiple locations, including Little Rock Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 55 Years
Countries United States, Argentina, Brazil, ...
Sponsor Eli Lilly and Company
Condition Schizophrenia Recruiting NCT07145918
The registry lists this study as recruiting. Study locations are listed in the United States.
Multiple locations, including Little Rock Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 65 Years
Countries United States
Sponsor AbbVie
Condition Schizophrenia Recruiting NCT07191483
The registry lists this study as recruiting. Study locations are listed in the United States.
Multiple locations, including Little Rock Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 55 Years
Countries United States
Sponsor Kynexis B.V.
Condition Schizophrenia Recruiting NCT07288567
The registry lists this study as recruiting. Study locations are listed in the United States, in Colombia, in Japan, ...
Multiple locations, including Anaheim Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 13 Years to 17 Years
Countries United States, Colombia, Japan, ...
Sponsor Bristol-Myers Squibb
Condition Schizophrenia Recruiting NCT06882785
The registry lists this study as recruiting. Study locations are listed in Japan.
Multiple locations, including Kōnan Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 65 Years
Countries Japan
Sponsor Bristol-Myers Squibb
Condition Schizophrenia Recruiting NCT07424404
The registry lists this study as recruiting. Study locations are listed in the United States, in Australia, in France, ...
Multiple locations, including Anaheim Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 5 Years to 17 Years
Countries United States, Australia, France, ...
Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition Schizophrenia Recruiting NCT07061288
The registry lists this study as recruiting. Study locations are listed in the United States.
Multiple locations, including Los Alamitos Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 55 Years
Countries United States
Sponsor Bristol-Myers Squibb
Condition Schizophrenia Recruiting NCT06894212
The registry lists this study as recruiting. Study locations are listed in the United States and in Japan.
Multiple locations, including Konan-shi Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 65 Years
Countries United States, Japan
Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition Schizophrenia